127 related articles for article (PubMed ID: 2392442)
1. Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites.
Kadlubar FF; Talaska G; Butler MA; Teitel CH; Massengill JP; Lang NP
Prog Clin Biol Res; 1990; 340B():107-14. PubMed ID: 2392442
[No Abstract] [Full Text] [Related]
2. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
McQuilkin SH; Nierenberg DW; Bresnick E
Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
[TBL] [Abstract][Full Text] [Related]
3. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity.
Cribb AE; Isbrucker R; Levatte T; Tsui B; Gillespie CT; Renton KW
Pharmacogenetics; 1994 Jun; 4(3):166-70. PubMed ID: 7920698
[TBL] [Abstract][Full Text] [Related]
4. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels.
Landi MT; Zocchetti C; Bernucci I; Kadlubar FF; Tannenbaum S; Skipper P; Bartsch H; Malaveille C; Shields P; Caporaso NE; Vineis P
Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):693-8. PubMed ID: 8877060
[TBL] [Abstract][Full Text] [Related]
6. Urinary biomarkers for assessing dietary exposure to caffeine.
Crews HM; Olivier L; Wilson LA
Food Addit Contam; 2001 Dec; 18(12):1075-87. PubMed ID: 11761118
[TBL] [Abstract][Full Text] [Related]
7. Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells.
Kloth MT; Gee RL; Messing EM; Swaminathan S
Carcinogenesis; 1994 Dec; 15(12):2781-7. PubMed ID: 8001235
[TBL] [Abstract][Full Text] [Related]
8. [HPLC determination of five caffeine metabolites].
Lu JF; Yi T; Cao XM; Zhuo HT; Lin SS
Yao Xue Xue Bao; 1997 Aug; 32(8):607-11. PubMed ID: 11596311
[TBL] [Abstract][Full Text] [Related]
9. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
Butler MA; Lang NP; Young JF; Caporaso NE; Vineis P; Hayes RB; Teitel CH; Massengill JP; Lawsen MF; Kadlubar FF
Pharmacogenetics; 1992 Jun; 2(3):116-27. PubMed ID: 1306111
[TBL] [Abstract][Full Text] [Related]
10. Determination of N-acetylation phenotyping in a Greek population using caffeine as a metabolic probe.
Asprodini EK; Zifa E; Papageorgiou I; Benakis A
Eur J Drug Metab Pharmacokinet; 1998; 23(4):501-6. PubMed ID: 10323334
[TBL] [Abstract][Full Text] [Related]
11. A simplified and rapid test for acetylator phenotyping by use of the peak height ratio of two urinary caffeine metabolites.
el-Yazigi A; Chaleby K; Martin CR
Clin Chem; 1989 May; 35(5):848-51. PubMed ID: 2566399
[TBL] [Abstract][Full Text] [Related]
12. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.
Jetter A; Kinzig-Schippers M; Illauer M; Hermann R; Erb K; Borlak J; Wolf H; Smith G; Cascorbi I; Sörgel F; Fuhr U
Eur J Clin Pharmacol; 2004 Mar; 60(1):17-21. PubMed ID: 14747882
[TBL] [Abstract][Full Text] [Related]
13. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells.
Frederickson SM; Messing EM; Reznikoff CA; Swaminathan S
Cancer Epidemiol Biomarkers Prev; 1994; 3(1):25-32. PubMed ID: 8118381
[TBL] [Abstract][Full Text] [Related]
14. A population and family study of N-acetyltransferase using caffeine urinary metabolites.
Bechtel YC; Bonaiti-Pellie C; Poisson N; Magnette J; Bechtel PR
Clin Pharmacol Ther; 1993 Aug; 54(2):134-41. PubMed ID: 8354022
[TBL] [Abstract][Full Text] [Related]
15. Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay.
Rihs HP; John A; Scherenberg M; Seidel A; Brüning T
Clin Chim Acta; 2007 Feb; 376(1-2):240-3. PubMed ID: 17011540
[TBL] [Abstract][Full Text] [Related]
16. Urinary excretion of an uracilic metabolite from caffeine by rat, monkey and man.
Latini R; Bonati M; Marzi E; Garattini S
Toxicol Lett; 1981 Jan; 7(3):267-72. PubMed ID: 7222102
[TBL] [Abstract][Full Text] [Related]
17. Acetylator status, drug metabolism and disease.
Pande JN; Pande A; Singh SP
Natl Med J India; 2003; 16(1):24-6. PubMed ID: 12715953
[TBL] [Abstract][Full Text] [Related]
18. Relationship between metabolic phenotype of N-acetylation and bladder cancer.
Cui X; Guo R; Xu Z; Wang B; Li C
Chin Med J (Engl); 2000 Apr; 113(4):303-5. PubMed ID: 11775223
[TBL] [Abstract][Full Text] [Related]
19. [Effect of various liver diseases on the activity of 2 subtypes of cytochrome P-450].
Balogh A; Simon HJ; Reinhardt M; Splinter FK; Traeger A
Dtsch Z Verdau Stoffwechselkr; 1987; 47(1):1-13. PubMed ID: 3582233
[TBL] [Abstract][Full Text] [Related]
20. Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism.
Winter HR; Unadkat JD
Drug Metab Dispos; 2005 Jul; 33(7):969-76. PubMed ID: 15843491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
